The Types segmentation categorizes services by analytical focus: Pharmacokinetics/Pharmacodynamics (PK/PD), Immunogenicity, Biomarker quantification, and ADME (Absorption, Distribution, Metabolism, Excretion). PK/PD assays dominate the portfolio, reflecting the need to characterize exposure‑response relationships for complex biologics; they contribute the greatest proportion of service fees due to frequent repeat measurements across study phases. Immunogenicity testing, essential for detecting anti‑drug antibodies, adds a critical safety layer and represents a growing niche as biologics become more prevalent. Biomarker quantification supports mechanism‑of‑action validation and patient stratification, driving incremental revenue through high‑value multiplexed platforms. ADME services, though less voluminous, are indispensable for understanding biotherapeutic disposition and inform dosing strategies. Together, these type sub‑segments define the functional scope of the market, each adding specialized expertise that collectively sustains the overall market size.